A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy

Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Motohiro Shimizu, Satoshi Hiramine, Fujiko Mitsumoto, Kazuya Ura, Kazuhiro Toyoda, Murata Masayuki, Jun Hayashi

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

Recently direct-acting antiviral agents, such as hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) protease inhibitors (PI), have been introduced, and triple therapy regimens that include PI with conventional pegylated interferon α and ribavirin have significantly improved the sustained virological response (SVR) rate, up to 80% for both treatment-naïve and treatment-experienced patients with HCV genotype 1. We here report for the first time a case of the successful treatment of HCV genotype 1 infection with a first generation PI drug (telaprevir) based triple therapy after treatment failure with a second generation PI drug (vaniprevir) based triple therapy. A 67-year-old treatment-naïve Japanese man with HCV genotype 1b infection took part in a phase III clinical trial of vaniprevir-based triple therapy. His serum HCV RNA had become undetectable at week 2 and SVR was highly expected, but HCV RNA reappeared at week 4 after vaniprevir treatment. Polymerase chain reaction direct sequence of the HCV NS3/4A gene at week 8 after vaniprevir treatment showed the emergence of a vaniprevir-resistance mutation (D168V), the probable reason for the treatment failure. Six months later, retreatment with telaprevir-based triple therapy was started. Although the dosages of telaprevir and ribavirin had to be reduced due to severe anemia, the patient achieved an SVR. This case shows the value of repeating PI-based triple therapy with a different drug, a process that would reduce the chance of drug resistant mutation.

元の言語英語
ページ(範囲)577-581
ページ数5
ジャーナルJournal of Infection and Chemotherapy
20
発行部数9
DOI
出版物ステータス出版済み - 1 1 2014

Fingerprint

Hepatitis C
Treatment Failure
Hepacivirus
Infection
Protease Inhibitors
Therapeutics
Ribavirin
Genotype
Pharmaceutical Preparations
MK-7009
telaprevir
RNA
Phase III Clinical Trials
Mutation
Retreatment
Interferons
Antiviral Agents
Anemia
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

これを引用

A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy. / Takayama, Koji; Furusyo, Norihiro; Ogawa, Eiichi; Shimizu, Motohiro; Hiramine, Satoshi; Mitsumoto, Fujiko; Ura, Kazuya; Toyoda, Kazuhiro; Masayuki, Murata; Hayashi, Jun.

:: Journal of Infection and Chemotherapy, 巻 20, 番号 9, 01.01.2014, p. 577-581.

研究成果: ジャーナルへの寄稿記事

@article{c6bd0a40908d496a8391bf4b7a5b690b,
title = "A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy",
abstract = "Recently direct-acting antiviral agents, such as hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) protease inhibitors (PI), have been introduced, and triple therapy regimens that include PI with conventional pegylated interferon α and ribavirin have significantly improved the sustained virological response (SVR) rate, up to 80{\%} for both treatment-na{\"i}ve and treatment-experienced patients with HCV genotype 1. We here report for the first time a case of the successful treatment of HCV genotype 1 infection with a first generation PI drug (telaprevir) based triple therapy after treatment failure with a second generation PI drug (vaniprevir) based triple therapy. A 67-year-old treatment-na{\"i}ve Japanese man with HCV genotype 1b infection took part in a phase III clinical trial of vaniprevir-based triple therapy. His serum HCV RNA had become undetectable at week 2 and SVR was highly expected, but HCV RNA reappeared at week 4 after vaniprevir treatment. Polymerase chain reaction direct sequence of the HCV NS3/4A gene at week 8 after vaniprevir treatment showed the emergence of a vaniprevir-resistance mutation (D168V), the probable reason for the treatment failure. Six months later, retreatment with telaprevir-based triple therapy was started. Although the dosages of telaprevir and ribavirin had to be reduced due to severe anemia, the patient achieved an SVR. This case shows the value of repeating PI-based triple therapy with a different drug, a process that would reduce the chance of drug resistant mutation.",
author = "Koji Takayama and Norihiro Furusyo and Eiichi Ogawa and Motohiro Shimizu and Satoshi Hiramine and Fujiko Mitsumoto and Kazuya Ura and Kazuhiro Toyoda and Murata Masayuki and Jun Hayashi",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.jiac.2014.06.002",
language = "English",
volume = "20",
pages = "577--581",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "9",

}

TY - JOUR

T1 - A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy

AU - Takayama, Koji

AU - Furusyo, Norihiro

AU - Ogawa, Eiichi

AU - Shimizu, Motohiro

AU - Hiramine, Satoshi

AU - Mitsumoto, Fujiko

AU - Ura, Kazuya

AU - Toyoda, Kazuhiro

AU - Masayuki, Murata

AU - Hayashi, Jun

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Recently direct-acting antiviral agents, such as hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) protease inhibitors (PI), have been introduced, and triple therapy regimens that include PI with conventional pegylated interferon α and ribavirin have significantly improved the sustained virological response (SVR) rate, up to 80% for both treatment-naïve and treatment-experienced patients with HCV genotype 1. We here report for the first time a case of the successful treatment of HCV genotype 1 infection with a first generation PI drug (telaprevir) based triple therapy after treatment failure with a second generation PI drug (vaniprevir) based triple therapy. A 67-year-old treatment-naïve Japanese man with HCV genotype 1b infection took part in a phase III clinical trial of vaniprevir-based triple therapy. His serum HCV RNA had become undetectable at week 2 and SVR was highly expected, but HCV RNA reappeared at week 4 after vaniprevir treatment. Polymerase chain reaction direct sequence of the HCV NS3/4A gene at week 8 after vaniprevir treatment showed the emergence of a vaniprevir-resistance mutation (D168V), the probable reason for the treatment failure. Six months later, retreatment with telaprevir-based triple therapy was started. Although the dosages of telaprevir and ribavirin had to be reduced due to severe anemia, the patient achieved an SVR. This case shows the value of repeating PI-based triple therapy with a different drug, a process that would reduce the chance of drug resistant mutation.

AB - Recently direct-acting antiviral agents, such as hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) protease inhibitors (PI), have been introduced, and triple therapy regimens that include PI with conventional pegylated interferon α and ribavirin have significantly improved the sustained virological response (SVR) rate, up to 80% for both treatment-naïve and treatment-experienced patients with HCV genotype 1. We here report for the first time a case of the successful treatment of HCV genotype 1 infection with a first generation PI drug (telaprevir) based triple therapy after treatment failure with a second generation PI drug (vaniprevir) based triple therapy. A 67-year-old treatment-naïve Japanese man with HCV genotype 1b infection took part in a phase III clinical trial of vaniprevir-based triple therapy. His serum HCV RNA had become undetectable at week 2 and SVR was highly expected, but HCV RNA reappeared at week 4 after vaniprevir treatment. Polymerase chain reaction direct sequence of the HCV NS3/4A gene at week 8 after vaniprevir treatment showed the emergence of a vaniprevir-resistance mutation (D168V), the probable reason for the treatment failure. Six months later, retreatment with telaprevir-based triple therapy was started. Although the dosages of telaprevir and ribavirin had to be reduced due to severe anemia, the patient achieved an SVR. This case shows the value of repeating PI-based triple therapy with a different drug, a process that would reduce the chance of drug resistant mutation.

UR - http://www.scopus.com/inward/record.url?scp=84906258459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906258459&partnerID=8YFLogxK

U2 - 10.1016/j.jiac.2014.06.002

DO - 10.1016/j.jiac.2014.06.002

M3 - Article

VL - 20

SP - 577

EP - 581

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 9

ER -